MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients
This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS. The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.
Chest x-ray (CXR)* revealing bilateral infiltrates involving a minimum of three... [+2]
Age less than 18 years. [+9]